Lumida
/AORT
⌘K
Artivion Inc

Artivion Inc

AORT
$25.08USD+1.74%+0.43 today

MARKET CAP

1.2B

P/E (TTM)

104.5x

FWD P/E

DAY RANGE

$24 – $25

52W RANGE

$19
$48

AI Summary

Stalk
Sell NowHigh

AORT remains in a medium-term downtrend after failing to reclaim the 9-, 20- and 50-day EMA cluster around the 26.00–26.50 area. Price is below all key short-term EMAs with declining slopes and has experienced clear downside follow-through. The broken support zone near 26 now offers a structurally appropriate resistance region to sell into any rally. Although oversold conditions may invite a relief bounce, EMA rejection and continuation signals favor further downside. A decisive reclaim and hold above the EMA cluster would invalidate this bearish bias.

  • 9% YoY revenue to $125.8M in Q2 2026 with 12% stent graft growth
  • AMDS approval expected to accelerate U.S. adoption mid‐2026
  • Negative $12M free cash flow in Q2 vs. +$11.7M prior year
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$313.8M$354.0M$388.5M$441.3M
YoY %+12.8%+9.8%+13.6%
P / Sales1.5x2.1x3.1x4.9x
EV / Sales2.9x3.3x4.2x5.7x
Gross Profit, Adj.$202.5M$229.2M$248.8M$284.2M
YoY %+13.2%+8.6%+14.2%
Margin %64.5%64.7%64.0%64.4%
EV / Gross Profit4.5x5.2x6.6x8.9x
EBITDA, Adj.$28.6M$14.6M$63.1M$49.2M
YoY %-49.1%+333.0%-22.0%
Margin %9.1%4.1%16.2%11.1%
EV / EBITDA31.8x81.2x26.2x51.3x
EBIT$6.2M$-8.5M$38.9M$26.7M
YoY %-237.2%+556.9%-31.2%
Margin %2.0%-2.4%10.0%6.1%
EV / EBIT146.8x-139.1x42.5x94.3x
Net Income$-19.2M$-30.7M$-13.4M$9.8M
YoY %-59.9%+56.5%+173.1%
Net Margin-6.1%-8.7%-3.4%2.2%
EPS (GAAP)-$0.48-$0.75-$0.32$0.21
YoY %-56.3%+57.3%+165.6%